Endo International (ENDP) Tops Q1 EPS by 10c, Revenues Beat; Offers FY19 EPS/Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Endo Reports First-Quarter 2019 Financial Results
May 9, 2019 6:30 AM EDTDUBLIN, May 9, 2019 /PRNewswire/ --
First-quarter 2019 revenues increased 3 percent to $720 million compared to first-quarter 2018 revenues of $701 million First-quarter 2019 Sterile Injectables revenues increased 25 percent to $270 million compared to first-quarter 2018 revenues of $216 million First-quarter 2019 Branded Pharmaceuticals - Specialty Products revenues increased 19 percent to $115 million compared to first-quarter 2018 revenues of $97 million Company affirms 2019 financial guidanceEndo International plc (NASDAQ: ENDP) today reported first-quarter 2019 financial results, including:
Revenues of $720 million, an increase of 3 percent compared to first-quarter 2018 revenues of $701... More